Pharmacogenomic considerations in opioid analgesia. [Corrigendum]

Pharmacogenomic considerations in opioid analgesia. [Corrigendum] Corrigendum (520) Total Article Views Authors: Vuilleumier PH, Stamer UM, Landau R Published Date January 2013 Volume 2013:6 Pages 1 - 2 DOI: http://dx.doi.org/10.2147/PGPM.S38356 Received: 20 September 2012 Accepted: 20 September 2012 Published: 14 January 2013 Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmacogenomics and Personalized Medicine. 2012;5:73–87. The authors regret an error in their Figure 1, CYP metabolism involved in opioid clearance. Read the original article Post to: Pharmacogenomic considerations in opioid analgesia. [Corrigendum]" >Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Dr Ruth Landau Pharmacogenomic considerations in opioid analgesia Readers of this article also read: Performance in L1 and L2 observed in Arabic-Hebrew bilingual aphasic following brain tumor: A case constitutes double dissociation The cognitive basis of diglossia in Arabic: Evidence from a repetition priming study within and between languages Amino acid-responsive Crohn's disease: a case study DataGenno: building a new tool to bridge molecular and clinical genetics Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor Pharmacogenomic considerations in opioid analgesia Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study A challenge to the seven widely believed concepts of COPD Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis